Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

Core Insights - Everest Medicines is hosting a virtual event on June 30, 2025, to discuss the latest results from the Phase 1b/2a clinical trial of EVER001, a next-generation covalent reversible BTK inhibitor for treating Primary Membranous Nephropathy (pMN) [1][2] Group 1: Clinical Trial and Treatment Landscape - The event will provide an overview of pMN and the current treatment landscape in the U.S. and China, along with the latest data from the EVER001 trial as of March 21, 2025 [2] - Everest recently reported positive preliminary results from the EVER001 study at the European Renal Association, with patient follow-up data as of December 14, 2024 [3] - There are approximately 2 million patients with pMN in China and nearly 220,000 patients in the U.S., Europe, and Japan, with no approved drugs for this condition globally [3][6] Group 2: About EVER001 - EVER001, previously known as XNW1011, is a next-generation covalent reversible BTK inhibitor being developed for renal diseases [5] - BTK is crucial for B-cell receptor signaling pathways that regulate B lymphocyte functions, and targeting BTK has shown effectiveness in treating B-cell lymphomas and autoimmune diseases [5] Group 3: About Primary Membranous Nephropathy (pMN) - pMN is a common pathological type of nephrotic syndrome in adults, with its prevalence in China increasing, ranking second only to IgA nephropathy [6] - The current treatment goals for pMN include improving remission rates, reducing relapse rates, and minimizing chronic toxicity risks from existing treatments [6] Group 4: About Everest Medicines - Everest Medicines focuses on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines to address unmet medical needs [7][8] - The management team has extensive expertise from leading global and local pharmaceutical companies, with a portfolio of potentially first-in-class or best-in-class molecules in renal diseases, infectious diseases, and autoimmune disorders [8]